Maia Butsashvili
Research Subjects
Research Interests
Maia Butsashvili has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- George Kamkamidze
Health Research Union/Clinic NEOLAB, Tbilisi, Georgia
11 shared publications George Kamkamidze
Health Research Union/Clinic NeoLab
7 shared publications- Shaun Shadaker
Division of Viral Hepatitis U.S. Centers for Disease Control and Prevention Atlanta Georgia USA
7 shared publications - Francisco Averhoff
Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC, Atlanta, USA
4 shared publications Lia Gvinjilia
TEPHINET
4 shared publicationsMuazzam Nasrullah
Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA
4 shared publications
Latest Publications
- 11 October 2026
- Published by Springer Nature in Journal of Ultrasound
- Vol. 29 (4) , 929-935
Ultrasound findings across liver fibrosis stages defined by transient elastography in patients with chronic hepatitis B in Georgia
Purpose Chronic hepatitis B (CHB) remains a major cause of chronic liver disease and may progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). This study aimed to evaluate conventional abdominal ultrasound (US) findings across liver fibrosis stages defined by transient elastography (TE) in patients with CHB. Methods In this cross-sectional study, 232 adults with CHB were included. Conventional abdominal US and TE data were available for 231 patients. US findings were evaluated in relation to liver fibrosis stages defined by TE-derived liver stiffness measurements. Differences in liver stiffness according to US findings were assessed using the independent-samples t-test. Results Patients with heterogeneous liver echotexture had significantly higher liver stiffness than those with normal liver echotexture (8.71 ± 6.89 vs. 5.65 ± 1.30 kPa; mean difference, 3.06 kPa; 95% CI 1.78–4.34 kPa; p < 0.001). Patients with splenomegaly had significantly higher liver stiffness than those without splenomegaly (17.31 ± 15.18 vs. 6.55 ± 2.82 kPa; mean difference, 10.77 kPa; 95% CI 2.00–19.54 kPa; p = 0.020). Among the 231 patients, 71.9% were classified as F0–F1, 21.6% as F2–F3, and 6.5% as F4. Four patients were diagnosed with HCC, including three with cirrhosis (F4) and one with F0–F1 fibrosis. Conclusions Conventional abdominal US findings, particularly heterogeneous liver echotexture and splenomegaly, were associated with higher liver stiffness in patients with CHB. These findings support the complementary role of conventional abdominal US in the comprehensive non-invasive evaluation of patients with CHB.
- 11 October 2026
- Published by Springer Nature in Journal of Ultrasound
- Vol. 29 (4) , 929-935
Ultrasound findings across liver fibrosis stages defined by transient elastography in patients with chronic hepatitis B in Georgia
Purpose Chronic hepatitis B (CHB) remains a major cause of chronic liver disease and may progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). This study aimed to evaluate conventional abdominal ultrasound (US) findings across liver fibrosis stages defined by transient elastography (TE) in patients with CHB. Methods In this cross-sectional study, 232 adults with CHB were included. Conventional abdominal US and TE data were available for 231 patients. US findings were evaluated in relation to liver fibrosis stages defined by TE-derived liver stiffness measurements. Differences in liver stiffness according to US findings were assessed using the independent-samples t-test. Results Patients with heterogeneous liver echotexture had significantly higher liver stiffness than those with normal liver echotexture (8.71 ± 6.89 vs. 5.65 ± 1.30 kPa; mean difference, 3.06 kPa; 95% CI 1.78–4.34 kPa; p < 0.001). Patients with splenomegaly had significantly higher liver stiffness than those without splenomegaly (17.31 ± 15.18 vs. 6.55 ± 2.82 kPa; mean difference, 10.77 kPa; 95% CI 2.00–19.54 kPa; p = 0.020). Among the 231 patients, 71.9% were classified as F0–F1, 21.6% as F2–F3, and 6.5% as F4. Four patients were diagnosed with HCC, including three with cirrhosis (F4) and one with F0–F1 fibrosis. Conclusions Conventional abdominal US findings, particularly heterogeneous liver echotexture and splenomegaly, were associated with higher liver stiffness in patients with CHB. These findings support the complementary role of conventional abdominal US in the comprehensive non-invasive evaluation of patients with CHB.
- Open Access
- 5 January 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25 (1)
Abnormal lipid profile in the context of liver steatosis measured by transient elastography: experiences from an outpatient endocrine clinic
Dyslipidaemia is a recognised risk factor for cardiovascular diseases which remain the leading cause of death worldwide. There is a knowledge gap whether t
- 5 January 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25 (1)
Open AccessAbnormal lipid profile in the context of liver steatosis measured by transient elastography: experiences from an outpatient endocrine clinic
Dyslipidaemia is a recognised risk factor for cardiovascular diseases which remain the leading cause of death worldwide. There is a knowledge gap whether t
- Open Access
- 28 May 2025
- Published by University Libraries, University at Albany, State University of New York
Epidemiology of blood-borne infections among Georgian health care workers
INTRO: The prevalence of hepatitis in central Asia is considered high (>8% endemnicity) by the World Health Organization. Universal precautions among healthcare workers (HCWs) and newborn vaccination programs are important public health interventions to reduce the spread of hepatitis and other blood borne pathogens. This comprehensive evaluation of the risk of blood borne pathogen exposure among HCWs in the Republic of Georgia measures the following: 1) nosocomial risk events; 2) prevalence of HIV, HBV and HCV among Georgian HCWs; 3) predictive factors for HCWs recommending HBV vaccination for children; 4) prevalence of and willingness to report behavioral risk factors among HCWs.
- 28 May 2025
- Published by University Libraries, University at Albany, State University of New York
Open AccessEpidemiology of blood-borne infections among Georgian health care workers
INTRO: The prevalence of hepatitis in central Asia is considered high (>8% endemnicity) by the World Health Organization. Universal precautions among healthcare workers (HCWs) and newborn vaccination programs are important public health interventions to reduce the spread of hepatitis and other blood borne pathogens. This comprehensive evaluation of the risk of blood borne pathogen exposure among HCWs in the Republic of Georgia measures the following: 1) nosocomial risk events; 2) prevalence of HIV, HBV and HCV among Georgian HCWs; 3) predictive factors for HCWs recommending HBV vaccination for children; 4) prevalence of and willingness to report behavioral risk factors among HCWs.
- Open Access
- 1 August 2024
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 73 (30) , 660-666
Progress Toward the Elimination of Hepatitis B and Hepatitis C in the Country of Georgia, April 2015–April 2024
This report describes progress toward eliminating hepatitis B and C in the country of Georgia.
- 1 August 2024
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 73 (30) , 660-666
Open AccessProgress Toward the Elimination of Hepatitis B and Hepatitis C in the Country of Georgia, April 2015–April 2024
This report describes progress toward eliminating hepatitis B and C in the country of Georgia.
- Open Access
- 4 May 2023
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 20 (5) , e1004121
Hepatitis C care cascade among patients with and without tuberculosis: Nationwide observational cohort study in the country of Georgia, 2015–2020
Background: The Eastern European country of Georgia initiated a nationwide hepatitis C virus (HCV) elimination program in 2015 to address a high burden of infection. Screening for HCV infection through antibody testing was integrated into multiple existing programs, including the National Tuberculosis Program (NTP). We sought to compare the hepatitis C care cascade among patients with and without tuberculosis (TB) diagnosis in Georgia between 2015 and 2019 and to identify factors associated with loss to follow-up (LTFU) in hepatitis C care among patients with TB. Methods and findings: Using national ID numbers, we merged databases of the HCV elimination program, NTP, and national death registry from January 1, 2015 to September 30, 2020. The study population included 11,985 adults (aged ≥18 years) diagnosed with active TB from January 1, 2015 through December 31, 2019, and 1,849,820 adults tested for HCV antibodies between January 1, 2015 and September 30, 2020, who were not diagnosed with TB during that time. We estimated the proportion of patients with and without TB who were LTFU at each step of the HCV care cascade and explored temporal changes. Among 11,985 patients with active TB, 9,065 (76%) patients without prior hepatitis C treatment were tested for HCV antibodies, of which 1,665 (18%) had a positive result; LTFU from hepatitis C care was common, with 316 of 1,557 (20%) patients with a positive antibody test not undergoing viremia testing and 443 of 1,025 (43%) patients with viremia not starting treatment for hepatitis C. Overall, among persons with confirmed viremic HCV infection, due to LTFU at various stages of the care cascade only 28% of patients with TB had a documented cure from HCV infection, compared to 55% among patients without TB. LTFU after positive antibody testing substantially decreased in the last 3 years, from 32% among patients diagnosed with TB in 2017 to 12% among those diagnosed in 2019. After a positive HCV antibody test, patients without TB had viremia testing sooner than patients with TB (hazards ratio [HR] = 1.46, 95% confidence intervals [CI] [1.39, 1.54], p < 0.001). After a positive viremia test, patients without TB started hepatitis C treatment sooner than patients with TB (HR = 2.05, 95% CI [1.87, 2.25], p < 0.001). In the risk factor analysis adjusted for age, sex, and case definition (new versus previously treated), multidrug-resistant (MDR) TB was associated with an increased risk of LTFU after a positive HCV antibody test (adjusted risk ratio [aRR] = 1.41, 95% CI [1.12, 1.76], p = 0.003). The main limitation of this study was that due to the reliance on existing electronic databases, we were unable to account for the impact of all confounding factors in some of the analyses. Conclusions: LTFU from hepatitis C care after a positive antibody or viremia test was high and more common among patients with TB than in those without TB. Better integration of TB and hepatitis C care systems can potentially reduce LTFU and improve patient outcomes both in Georgia and other countries that are initiating or scaling up their nationwide hepatitis C control efforts and striving to provide personalized TB treatment.
- 4 May 2023
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 20 (5) , e1004121
Open AccessHepatitis C care cascade among patients with and without tuberculosis: Nationwide observational cohort study in the country of Georgia, 2015–2020
Background: The Eastern European country of Georgia initiated a nationwide hepatitis C virus (HCV) elimination program in 2015 to address a high burden of infection. Screening for HCV infection through antibody testing was integrated into multiple existing programs, including the National Tuberculosis Program (NTP). We sought to compare the hepatitis C care cascade among patients with and without tuberculosis (TB) diagnosis in Georgia between 2015 and 2019 and to identify factors associated with loss to follow-up (LTFU) in hepatitis C care among patients with TB. Methods and findings: Using national ID numbers, we merged databases of the HCV elimination program, NTP, and national death registry from January 1, 2015 to September 30, 2020. The study population included 11,985 adults (aged ≥18 years) diagnosed with active TB from January 1, 2015 through December 31, 2019, and 1,849,820 adults tested for HCV antibodies between January 1, 2015 and September 30, 2020, who were not diagnosed with TB during that time. We estimated the proportion of patients with and without TB who were LTFU at each step of the HCV care cascade and explored temporal changes. Among 11,985 patients with active TB, 9,065 (76%) patients without prior hepatitis C treatment were tested for HCV antibodies, of which 1,665 (18%) had a positive result; LTFU from hepatitis C care was common, with 316 of 1,557 (20%) patients with a positive antibody test not undergoing viremia testing and 443 of 1,025 (43%) patients with viremia not starting treatment for hepatitis C. Overall, among persons with confirmed viremic HCV infection, due to LTFU at various stages of the care cascade only 28% of patients with TB had a documented cure from HCV infection, compared to 55% among patients without TB. LTFU after positive antibody testing substantially decreased in the last 3 years, from 32% among patients diagnosed with TB in 2017 to 12% among those diagnosed in 2019. After a positive HCV antibody test, patients without TB had viremia testing sooner than patients with TB (hazards ratio [HR] = 1.46, 95% confidence intervals [CI] [1.39, 1.54], p < 0.001). After a positive viremia test, patients without TB started hepatitis C treatment sooner than patients with TB (HR = 2.05, 95% CI [1.87, 2.25], p < 0.001). In the risk factor analysis adjusted for age, sex, and case definition (new versus previously treated), multidrug-resistant (MDR) TB was associated with an increased risk of LTFU after a positive HCV antibody test (adjusted risk ratio [aRR] = 1.41, 95% CI [1.12, 1.76], p = 0.003). The main limitation of this study was that due to the reliance on existing electronic databases, we were unable to account for the impact of all confounding factors in some of the analyses. Conclusions: LTFU from hepatitis C care after a positive antibody or viremia test was high and more common among patients with TB than in those without TB. Better integration of TB and hepatitis C care systems can potentially reduce LTFU and improve patient outcomes both in Georgia and other countries that are initiating or scaling up their nationwide hepatitis C control efforts and striving to provide personalized TB treatment.
- Open Access
- 28 March 2022
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 17 (1) , 1-6
Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia
Background: People who inject drugs (PWID) in Georgia have a high prevalence of hepatitis C virus antibody (anti-HCV). Access to care among PWID could be prioritized to meet the country’s hepatitis C elimination goals. This study assesses barriers of linkage to HCV viremia testing among PWID in Georgia. Methods: Study participants were enrolled from 13 harm reduction (HR) centers throughout Georgia. Anti-HCV positive PWID who were tested for viremia (complete diagnosis [CD]), were compared to those not tested for viremia within 90 days of screening anti-HCV positive (not complete diagnosis [NCD]). Convenience samples of CD and NCD individuals recorded at HR centers using beneficiaries’ national ID were drawn from the National HCV Elimination Program database. Participants were interviewed about potential barriers to seeking care. Results: A total of 500 PWID were enrolled, 245 CD and 255 NCD. CD and NCD were similar with respect to gender, age, employment status, education, knowledge of anti-HCV status, and confidence/trust in the elimination program (p > 0.05). More NCD (13.0%) than CD (7.4%) stated they were not sufficiently informed what to do after screening anti-HCV positive (p < 0.05). In multivariate analysis, HCV viremia testing was associated with perceived affordability of the elimination program (adjusted prevalence ratio = 8.53; 95% confidence interval: 4.14–17.62). Conclusions: Post testing counselling and making hepatitis C services affordable could help increase HCV viremia testing among PWID in Georgia.
- 28 March 2022
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 17 (1) , 1-6
Open AccessBarriers of linkage to HCV viremia testing among people who inject drugs in Georgia
Background: People who inject drugs (PWID) in Georgia have a high prevalence of hepatitis C virus antibody (anti-HCV). Access to care among PWID could be prioritized to meet the country’s hepatitis C elimination goals. This study assesses barriers of linkage to HCV viremia testing among PWID in Georgia. Methods: Study participants were enrolled from 13 harm reduction (HR) centers throughout Georgia. Anti-HCV positive PWID who were tested for viremia (complete diagnosis [CD]), were compared to those not tested for viremia within 90 days of screening anti-HCV positive (not complete diagnosis [NCD]). Convenience samples of CD and NCD individuals recorded at HR centers using beneficiaries’ national ID were drawn from the National HCV Elimination Program database. Participants were interviewed about potential barriers to seeking care. Results: A total of 500 PWID were enrolled, 245 CD and 255 NCD. CD and NCD were similar with respect to gender, age, employment status, education, knowledge of anti-HCV status, and confidence/trust in the elimination program (p > 0.05). More NCD (13.0%) than CD (7.4%) stated they were not sufficiently informed what to do after screening anti-HCV positive (p < 0.05). In multivariate analysis, HCV viremia testing was associated with perceived affordability of the elimination program (adjusted prevalence ratio = 8.53; 95% confidence interval: 4.14–17.62). Conclusions: Post testing counselling and making hepatitis C services affordable could help increase HCV viremia testing among PWID in Georgia.
- Open Access
- 16 March 2022
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 29 (2) , 134-136
Door-to-door hepatitis C screening in Georgia: An innovative model to increase testing and linkage to care
Objectives: Georgia has a high prevalence of hepatitis C virus (HCV) infection. In 2015 a national HCV elimination program was launched providing free access to screening and treatment. To achieve elimination, innovative approaches to increase screening coverage and linkage to care are needed. This study estimates feasibility, acceptability, and outcomes of the door-to-door pilot HCV testing program in three cities. Methods: Households were approached by system random sampling and all members were invited for study participation. Researchers used a detailed guide for conducting door-to-door testing and served as case navigators to link anti-HCV-positive individuals to care. Results: Testing acceptance rate was high. In total 4804 individuals were tested and 48 (1.0%) were HCV positive. Among the entire sample of newly and previously tested individuals, overall HCV antibody prevalence was 3.6%. Through case navigation, of 48 newly identified and 26 previously identified anti-HCV-positive individuals, 42 (87.5%) and 17 (65.4%), respectively, were successfully linked to care. Conclusions: Door-to-door HCV testing has potential to increase testing uptake. Such community-based approaches not only improve testing, but can also serve to increase linkage to care, which is important in achieving the goal of HCV elimination. The study provides a model for high prevalence countries aiming to eliminate hepatitis C.
- 16 March 2022
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 29 (2) , 134-136
Open AccessDoor-to-door hepatitis C screening in Georgia: An innovative model to increase testing and linkage to care
Objectives: Georgia has a high prevalence of hepatitis C virus (HCV) infection. In 2015 a national HCV elimination program was launched providing free access to screening and treatment. To achieve elimination, innovative approaches to increase screening coverage and linkage to care are needed. This study estimates feasibility, acceptability, and outcomes of the door-to-door pilot HCV testing program in three cities. Methods: Households were approached by system random sampling and all members were invited for study participation. Researchers used a detailed guide for conducting door-to-door testing and served as case navigators to link anti-HCV-positive individuals to care. Results: Testing acceptance rate was high. In total 4804 individuals were tested and 48 (1.0%) were HCV positive. Among the entire sample of newly and previously tested individuals, overall HCV antibody prevalence was 3.6%. Through case navigation, of 48 newly identified and 26 previously identified anti-HCV-positive individuals, 42 (87.5%) and 17 (65.4%), respectively, were successfully linked to care. Conclusions: Door-to-door HCV testing has potential to increase testing uptake. Such community-based approaches not only improve testing, but can also serve to increase linkage to care, which is important in achieving the goal of HCV elimination. The study provides a model for high prevalence countries aiming to eliminate hepatitis C.
- Open Access
- 23 August 2021
- Published by Springer Nature in Research Square
Barriers of Linkage to Hepatitis C Care and Treatment Among People Who Inject Drugs in Georgia
Background: People who inject drugs (PWID) in Georgia have a high prevalence of hepatitis C virus antibody (anti-HCV). Access to care among PWID could be prioritized to meet the country’s hepatitis C elimination goals. This study assesses barriers of linkage to hepatitis C care among PWID in Georgia.Methods: Study participants were enrolled from 13 harm reduction centers throughout Georgia. Anti-HCV positive PWID who were tested for viremia (linked to care [LC]), were compared to those not tested for viremia within 90 days of screening anti-HCV positive (not linked to care [NLC]). Participants were interviewed about potential barriers to seeking care.Results: A total of 500 PWID were enrolled, 245 LC and 255 NLC. LC and NLC were similar with respect to gender, age, employment status, education, knowledge of anti-HCV status, and confidence/trust in the elimination program (p>0.05). More NLC (13.0%) than LC (7.4%) stated they were not sufficiently informed what to do after screening anti-HCV positive (pConclusions: Post testing counselling and making hepatitis C services affordable could help increase linkage to care among PWID in Georgia.
- 23 August 2021
- Published by Springer Nature in Research Square
Open AccessBarriers of Linkage to Hepatitis C Care and Treatment Among People Who Inject Drugs in Georgia
Background: People who inject drugs (PWID) in Georgia have a high prevalence of hepatitis C virus antibody (anti-HCV). Access to care among PWID could be prioritized to meet the country’s hepatitis C elimination goals. This study assesses barriers of linkage to hepatitis C care among PWID in Georgia.Methods: Study participants were enrolled from 13 harm reduction centers throughout Georgia. Anti-HCV positive PWID who were tested for viremia (linked to care [LC]), were compared to those not tested for viremia within 90 days of screening anti-HCV positive (not linked to care [NLC]). Participants were interviewed about potential barriers to seeking care.Results: A total of 500 PWID were enrolled, 245 LC and 255 NLC. LC and NLC were similar with respect to gender, age, employment status, education, knowledge of anti-HCV status, and confidence/trust in the elimination program (p>0.05). More NLC (13.0%) than LC (7.4%) stated they were not sufficiently informed what to do after screening anti-HCV positive (pConclusions: Post testing counselling and making hepatitis C services affordable could help increase linkage to care among PWID in Georgia.
- 31 July 2020
- Published by Elsevier in International Journal of Drug Policy
- Vol. 84, 102893
Integration of hepatitis C treatment at harm reduction centers in Georgia—Findings from a patient satisfaction survey
- 31 July 2020
- Published by Elsevier in International Journal of Drug Policy
- Vol. 84, 102893
Integration of hepatitis C treatment at harm reduction centers in Georgia—Findings from a patient satisfaction survey